Intrinsic Bioprobes, of Tempe, Ariz.,a privately held biotechnology company, has licensed two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, Inc., of Raritan, N.J. The biomarkers are modified forms of proteins circulating in the blood and have been linked with the presence of diabetes and prediabetes.

The discovery of the biomarkers was supported in part by a five-year, $2 million grant from the National Institutes of Health to Intrinsic Bioprobes, in collaboration with researchers at Yale University in New Haven, Conn.

“The biomarkers were extensively tested and shown to have statistically significant clinical sensitivities and specificities in differentiating subjects with pre- and type-2 diabetes from health controls,” said Urban Kiernan, PhD, Director of Biomarker Discovery at Intrinsic Bioprobes.

Continue Reading